Clinical Trial Update: Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing intraperitoneal plus systemic chemotherapy to XELOX as first-line treatment for metastatic colorectal cancer. Current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer Metastatic

Drugs mentioned

• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Colorectal Cancer Metastatic, Chemotherapy Effect | Phase 2 | Status: UNKNOWN